Medtronic Stock-based compensation expense increased by 55.3% to $146.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 3.9%, from $152.00M to $146.00M. This is a positive signal — lower values indicate better performance for this metric.
Rising expenses may indicate increased reliance on equity incentives or higher valuation of awards, impacting reported operating margins.
This metric measures the total expense recognized in the income statement for share-based payment awards granted to empl...
Standard operating expense item for public companies with equity incentive programs.
cat_stock_based_compensation_expense| Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $107.00M | $92.00M | $49.00M | $41.00M | $55.00M | $48.00M | $73.00M | $35.00M | $49.00M | $87.00M | $103.00M | $152.00M | $93.00M | $94.00M | $146.00M |
| QoQ Change | — | -14.0% | -46.7% | -16.3% | +34.1% | -12.7% | +52.1% | -52.1% | +40.0% | +77.6% | +18.4% | +47.6% | -38.8% | +1.1% | +55.3% |
| YoY Change | — | — | — | -61.7% | -40.2% | -2.0% | +78.0% | -36.4% | +2.1% | +19.2% | +194.3% | +210.2% | +6.9% | -8.7% | -3.9% |